Protagonist Therapeutics, INC (PTGX) — 10-Q Filings

10-Q Filings (6)

• Protagonist Swings to Loss on Plummeting Collaboration Revenue — Nov 6, 2025 Risk: medium
  Protagonist Therapeutics, Inc. (PTGX) reported a significant decline in revenue and a net loss for the nine months ended September 30, 2025, primarily due to a
• Protagonist's Q2 Loss Widens to $35.2M Amid Rusfertide Development — Aug 6, 2025 Risk: high
  Protagonist Therapeutics, Inc. reported a net loss of $35.2 million for the quarter ended June 30, 2025, a significant increase from the $28.5 million net loss
• Protagonist Therapeutics Files Q1 2025 10-Q — May 6, 2025 Risk: low
  Protagonist Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial position and operational updates.
• Protagonist Therapeutics Q3 2024 Update: Cash Up, Financing Activities Detailed — Nov 7, 2024 Risk: medium
  Protagonist Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported cash and cash equivalents of $57.7 million as of De
• Protagonist Therapeutics Q2 2024: Net Loss of $24.1M — Aug 6, 2024 Risk: medium
  Protagonist Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $57.7 million and total liabilities of $
• Protagonist Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk: medium
  Protagonist Therapeutics, Inc (PTGX) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Protagonist Therapeutics, Inc. filed a 10-Q report for the per

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX